Joint Clinical Assessments – Mandatory EU-Level Evaluations for Health Technology Assessment

EU Regulation 2021/2282 on Health Technology Assessment (HTA) is now in force, bringing important changes. The key implication is the introduction of EU-level Joint Clinical Assessments (JCAs) that will be applied to companies in a stepwise fashion starting in January 2025. These assessments evaluate treatment effectiveness and will affect authorized medicines and medical devices and aims to reduce the time to medicines access across EU member states.

 This white paper authored by NDA Advisory Board member, Dr Sigrid Klaar, provides a comprehensive overview of the JCA procedure for medicines.

 

Download 

Fill out the form on the right to download this content. 

  • This field is for validation purposes and should be left unchanged.

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.